Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U01 AI142756)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1 HG009490)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01 EB022376)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM118062)
United States Department of Defense | Defense Advanced Research Projects Agency (HR0011-17-2-0049)
Article History
Received: 13 February 2019
Accepted: 4 April 2019
First Online: 17 May 2019
Competing interests
: D.R.L. is a consultant and co-founder of Editas Medicine, Beam Therapeutics, and Pairwise Plants, companies that use genome editing. H.A.R. and D.R.L have filed a patent application on RDN-mediated genome editing. H.A.R and D.R.L are co-inventors on a provisional patent application filed by the Broad Institute covering the use of hRad51 and its variants fused to nickases for enhanced HDR. The remaining author declares no competing interests.